Vascularized Composite Allotransplantation (VCA) Research & Development

The contract pertains to advanced research and development in vascularized composite allotransplantation, focusing on high-risk, high-reward scientific objectives that include surgical innovation, immunomodulation strategies, and tissue integration mechanisms. The work demands the development of novel techniques and methodologies aimed at improving transplant outcomes, with deliverables structured around clearly defined milestones that require rigorous data collection and transparent research resource sharing to ensure scientific advancement and reproducibility. This subcontract is issued by the Department of the Army through USAMRAA under the Department of Defense, targeting cutting-edge biomedical science within the NAICS code 541715, which classifies research and development in the physical, engineering, and life sciences. The opportunity was posted on June 17, 2026, with a response deadline of September 16, 2026, indicating a tight window for proposers to submit comprehensive research plans. While no specific set-aside provisions or location details are provided, the place of performance and point of contact remain undefined, suggesting the work may be conducted at the awardee’s facility or a collaborative research environment aligned with the Department of Defense’s strategic goals. The emphasis on data-driven milestones and resource sharing reflects a commitment to open scientific progress, ensuring that breakthroughs contribute broadly to the field of transplant medicine and serve national defense and medical readiness objectives.